Rapid doxorubicin efflux from the nucleus of drug-resistant cancer cells following extracellular drug clearance

Pharmaceutical Research

Volumn 24, Issue 11, 2007, Pages 2156-2167

  Chen, Vivien Y ^a   Posada, Maria M ^a   Zhao, Lili ^a   Rosania, Gus R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cellular pharmacokinetics; Doxorubicin; Drug delivery; Drug resistance; Drug sequestration; Drug targeting; Multivesicular body

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; TRITON X 100;

ARTICLE; CANCER RESISTANCE; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS; CELL PH; CELL STRAIN K 562; CELL VACUOLE; CELL VIABILITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACTIVE TRANSPORT, CELL NUCLEUS; ADENOSINE TRIPHOSPHATE; AMMONIUM CHLORIDE; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CYTOPLASM; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; HUMANS; K562 CELLS; MEMBRANE FUSION; METABOLIC CLEARANCE RATE;

EID: 34848889695     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9369-2     Document Type: Article

References (40)

1. R. Safaei, B. J. Larson, T. C. Cheng, M. A. Gibson, S. Otani, W. Naerdemann, and S. B. Howell. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol. Cancer Ther. 4:1595-1604 (2005).
2. Y. Gong, M. Duvvuri, M. B. Duncan, J. Liu, and J. P. Krise. Niemann-Pick C1 protein facilitates the efflux of the anticancer drug daunorubicin from cells according to a novel vesicle-mediated pathway. J. Pharmacol. Exp. Ther. 316:242-247 (2006).
3. A. Rajagopal and S. M. Simon. Subcellular localization and activity of multidrug resistance proteins. Mol. Biol. Cell 14:3389-3399 (2003).
4. V. Y. Chen and G. R. Rosania. The great multidrug-resistance paradox. ACS Chem. Biol. 1:271-273 (2006).
5. C. de Duve, T. de Barsy, B. Poole, A. Trouet, P. Tulkens, and F. Van Hoof. Commentary. Lysosomotropic agents. Biochem. Pharmacol. 23:2495-2531 (1974).
6. F. Rashid, R. W. Horobin, and M. A. Williams. Predicting the behaviour and selectivity of fluorescent probes for lysosomes and related structures by means of structure-activity models. Histochem. J. 23:450-459 (1991).
7. Y. Gong, M. Duvvuri, and J. P. Krise. Separate roles for the Golgi apparatus and lysosomes in the sequestration of drugs in the multidrug-resistant human leukemic cell line HL-60. J. Biol. Chem. 278:50234-50239 (2003).
8. L. Wu, A. M. Smythe, S. F. Stinson, L. A. Mullendore, A. Monks, D. A. Scudiero, K. D. Paull, A. D. Koutsoukos, L. V. Rubinstein, M. R. Boyd. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res. 52:3029-3034 (1992).
9. P. Ferrao, P. Sincock, S. Cole, and L. Ashman. Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia. Leuk. Res. 25:395-405 (2001).
10. V. Noskova, P. Dzubak, G. Kuzmina, A. Ludkova, D. Stehlik, R. Trojanec, A. Janostakova, G. Korinkova, V. Mihal, and M. Hajduch. In vitro chemoresistance profile and expression/function of MDR associated proteins in resistant cell lines derived from CCRF-CEM, K562, A549 and MDA MB 231 parental cells. Neoplasma 49:418-425 (2002).
11. H. Tapiero, G. Nguyen-Ba, and T. J. Lampidis. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells. Pathol. Biol. 42:328-337 (1994).
12. V. Y. Chen, M. M. Posada, L. L. Blazer, T. Zhao, and G. R. Rosania. The role of the VPS4A-exosome pathway in the intrinsic egress route of a DNA-binding anticancer drug. Pharm. Res. 23:1687-1695 (2006).
13. S. M. Simon and M. Schindler. Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. U S A 91:3497-3504 (1994).
14. T. Hayon, A. Dvilansky, O. Shpilberg, and I. Nathan. Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia. Leuk. Lymphoma. 44:1957-1962 (2003).
15. D. Marquardt and M. S. Center. Drug transport mechanisms in HL60 Cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells. Cancer Res. 52:3157-3163 (1992).
16. W. J. Betz, F. Mao, and C. B. Smith. Imaging exocytosis and endocytosis. Curr. Opin. Neurobiol. 6:365-371 (1996).
17. A. Savina, M. Vidal, and M. I. Colombo. The exosome pathway in K562 cells is regulated by Rab11. J. Cell. Sci. 115:2505-2515 (2002).
18. D. J. Katzmann, G. Odorizzi, and S. D. Emr. Receptor downregulation and multivesicular-body sorting. Nat. Rev. Mol. Cell. Biol. 3:893-905 (2002).
19. A. F. Fomina, T. J. Deerinck, M. H. Ellisman, and M. D. Cahalan. Regulation of membrane trafficking and subcellular organization of endocytic compartments revealed with FM1-43 in resting and activated human T cells. Exp. Cell Res. 291:150-166 (2003).
20. S. Ohkuma and B. Poole. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl. Acad. Sci. U S A 75:3327-3331 (1978).
21. J. Ishizaki, K. Yokogawa, M. Hirano, E. Nakashima, Y. Sai, S. Ohkuma, T. Ohshima, and F. Ichimura. Contribution of lysosomes to the subcellular distribution of basic drugs in the rat liver. Pharm. Res. 13:902-906 (1996).
22. C. Millot, J. M. Millot, H. Morjani, A. Desplaces, and M. Manfait. Characterization of acidic vesicles in multidrug-resistant and sensitive cancer cells by acridine orange staining and confocal microspectrofluorometry. J. Histochem. Cytochem. 45:1255-1264 (1997).
23. W. A. Daniel, J. Wojcikowski, and A. Palucha. Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping. Br. J. Pharmacol. 134:807-814 (2001).
24. T. Haller, P. Dietl, P. Deetjen, and H. Volkl. The lysosomal compartment as intracellular calcium store in MDCK cells: a possible involvement in InsP3-mediated Ca2+ release. Cell Calcium. 19:157-165 (1996).
25. L. Fang, G. Zhang, C. Li, X. Zheng, L. Zhu, J. J. Xiao, G. Szakacs, J. Nadas, K. K. Chan, P. G. Wang, and D. Sun. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance. J. Med. Chem. 49:932-941 (2006).
26. M. Page. High-volume screening. In B. A. Teicher (ed), Anticancer Drug Development Guide, Humana, Totowa, 1997, pp. 3-21.
27. P. A. Speth, Q. G. van Hoesel, and C. Haanen. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet. 15:15-31 (1988).
28. F. M. Balis, J. S. Holcenberg, and W. A. Bleyer. Clinical pharmacokinetics of commonly used anticancer drugs. Clin. Pharmacokinet. 8:202-232 (1983).
29. J. Vaage, E. Barbera-Guillem, R. Abra, A. Huang, and P. Working. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73:1478-1484 (1994).
30. D. W. Northfelt, F. J. Martin, P. Working, P. A. Volberding, J. Russell, M. Newman, M. A. Amantea, and L. D. Kaplan. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol. 36:55-63 (1996).
31. K. Shedden, X. T. Xie, P. Chandaroy, Y. T. Chang, and G. R. Rosania. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res. 63:4331-4337 (2003).
32. D. A. Tyrrell, T. D. Heath, C. M. Colley, and B. E. Ryman. New aspects of liposomes. Biochim. Biophys. Acta 457:259-302 (1976).
33. E. Goormaghtigh, P. Chatelain, J. Caspers, and J. M. Ruysschaert. Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochim. Biophys. Acta 597:1-14 (1980).
34. M. Duvvuri and J. P. Krise. A novel assay reveals that weakly basic model compounds concentrate in lysosomes to an extent greater than pH-partitioning theory would predict. Mol. Pharm. 2:440-448 (2005).
35. M. Babst. A protein's final ESCRT. Traffic 6:2-9 (2005).
36. N. Anderson and J. Borlak. Drug-induced phospholipidosis. FEBS Lett. 580:5533-5540 (2006).
37. B. T. Pan, K. Teng, C. Wu, M. Adam, and R. M. Johnstone. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J. Cell Biol. 101:942-948 (1985).
38. G. Raposo, H. W. Nijman, W. Stoorvogel, R. Liejendekker, C. V. Harding, C. J. Melief, and H. J. Geuze. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183:1161-1172 (1996).
39. T. A. Chan, H. Hermeking, C. Lengauer, K. W. Kinzler, and B. Vogelstein. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401:616-620 (1999).
40. K. Kiyomiya, S. Matsuo, and M. Kurebe. Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex. Cancer Res. 61:2467-2471 (2001).